Skip to content
JoelGalvan

JoelGalvan

View Video Stories
  • Home
  • Business
  • Culture
  • Sports
  • Home
  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.
  • Home
  • AntiTL1A

Tag: AntiTL1A

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Posted in Business

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Estimated read time 14 min read
Posted on February 22, 2025
by Joelgalvan

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing…

Learn More Leave a Comment on Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Recent Posts

  • Nathan Rourke shines as Lions beat Elks to cap Week 1 of CFL season
  • ‘Indians more mindful of money’: Ted Sarandos tells Nikhil Kamath why Netflix India is tricky
  • Broadcom Slips After Earnings Beat, Drags Down Tech ETFs
  • Rhose Almendralejo’s record game still not enough to lift Bacolod
  • Fund Manager Talk | Markets may move in 5% range till festive season: Trideep Bhattacharya

Recent Comments

No comments to show.

Archives

  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.